This study looked at the effectiveness of probiotic in reducing hepatic inflammation among non-alcohol fatty liver disease (NAFLD) patients ⁽¹⁾. The researchers searched the literature and 6 articles were finally critically appraised. All studies had good validity and reported unanimously that probiotic is useful in reducing hepatic inflammation and liver fat content. However, further evidence is required to show whether or not it is beneficial in reducing cirrhosis progression and liver-related mortality, as well as a differentiating the impact of different strains and doses.